The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,619,668 project grant to The University of Texas MD Anderson Cancer Center to inhibit brain metastases of HER2/neu-positive breast cancers using extracellular vesicles from renovated dendritic cells. The award began on May 1, 2024 and is scheduled for completion on April 30, 2027. The project aims to develop innovative treatments to improve outcomes for military service members and the broader population affected by this type of cancer. As a leading cancer research institution, MD Anderson has a strong track record of conducting impactful basic, translational, and clinical research funded by federal agencies like the Department of Defense.
Generated 1/14/25, 7:57 AM